Anlon Healthcare Ltd (AHCL)

📊 Quarterly Results (₹ Cr)

Revenue has surged from ₹33 crores in June 2025 to ₹87.62 crores in June 2026, reflecting both organic growth and acquisition-driven expansion. Operating margins remain volatile — peaking at 33.5% in December 2025 — but have stabilized around 16.6% in the latest quarter, likely due to integration costs and elevated raw material prices. PAT margins improved to ₹8.28 crores in Q1 FY27 from ₹4 crores a year ago, but EBITDA margins are expected to normalize to 25-28% only by FY27 end as scale takes effect. The company is reinvesting heavily, with CAPEX of ₹130 crores planned, funded partly through equity issuance, indicating a focus on long-term infrastructure over short-term returns.

🔮 Management Outlook & What's Next

Management is confident in achieving 30% revenue CAGR over three years while maintaining EBITDA margins of 25%-30%. They expect PAT margins to reach 12-13% in FY27 and EBITDA margins to normalize to 25-28% by FY27 end, supported by capacity expansion and price pass-through of elevated raw material costs. Integration of newly acquired entities is expected to drive synergies from FY28 onward. Management also highlighted confidence in statutory approvals and unchanged financing plans, reinforcing execution credibility. Investor presentations emphasize scaling as the core value driver, with profitability anticipated to improve as volumes and integration progress.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

The balance sheet shows a significant rise in equity and reserves — from ₹81 crores (₹40 + ₹41) in March 2025 to ₹230 crores (₹53 + ₹177) in March 2026 — reflecting capital infusion, likely from equity raises tied to acquisitions. Borrowings decreased from ₹67 crores to ₹44 crores, suggesting active deleveraging or reduced reliance on debt amid growing equity base. Total assets more than doubled to ₹374 crores, driven by investments in fixed assets and acquisitions. This indicates a strategic shift toward equity financing and balance sheet strengthening to support aggressive expansion, though it dilutes existing shareholders through new share issuances.

💰 Cash Flow Statement (₹ Cr)

👥 Shareholding Pattern

Promoter holding remains stable at 52.68%, but institutional interest has grown — FII shareholding rose from 0% in Q2FY26 to 1.67% in Q1FY27, and DII from 2.83% to 1.22%. The number of public shareholders has increased from 11,412 to 34,671, indicating broader retail interest. However, FII and DII allocations remain low relative to market cap, suggesting limited institutional depth. No pledging activity is reported, and the shareholder base is broadening, which may support liquidity over time. The recent equity issuance for acquisitions may further diversify ownership but could pressure promoter control in the short term.

⚖️ Peer Comparison — Pharmaceuticals

🔗 Peer Stock Analyses

⚠️ Risk Factors

1. Execution risk in integrating acquired businesses and completing share swap deals within 90 days amid regulatory hurdles. 2. Margin pressure from elevated raw material costs and integration expenses, despite price pass-through expectations. 3. High CAPEX and equity dilution from acquisitions may strain near-term cash flows, as seen in negative OCF of ₹-23 crores in FY25. 4. Dependence on a few large customers or suppliers in the API and formulations space could impact pricing and supply stability. 5. Market acceptance of expanded capacity in a potentially oversupplied pharmaceutical intermediates market.

📋 Recent Filings

• Announcement2026-09-28Anlon Healthcare Limited has announced a trading window closure for insiders effective October 1, 2026, until 48 hours after its unaudited quarterly r…
• 🔴 Announcement2026-09-24Anlon Healthcare Limited announced on September 24, 2026 that its management will attend the Arihant Capital BHARAT CONNECT CONFERENCE RISING STARS 20…
• 🟡 Board Meeting2026-09-21Anlon Healthcare Limited approved a share swap involving Apiqo Organics and Bizotic Lifescience at its September 5, 2026 AGM, with shareholders endors…
• 🔴 Announcement2026-09-21Anlon Healthcare announced incorporation of its Nigerian subsidiary, ANLON HEALTHCARE NIGERIA LIMITED, effective September 20, 2026, to expand pharmac…
• Announcement2026-09-17Anlon Healthcare clarified that recent price movement in its shares is purely market-driven with no undisclosed information affecting the stock, reaff…
• 🔴 Announcement2026-09-15Anlon Healthcare Limited received a BBB/Stable long-term credit rating from Brickwork Ratings for its ₹23.60 crore fund-based facilities, reflecting s…
• 🟡 Board Meeting2026-09-07Anlon Healthcare held its 13th AGM on September 5, 2026 via video conference, adopting audited standalone and consolidated financial statements for FY…
• 🟡 voting results2026-09-05At the AGM on September 5, 2026, shareholders approved all 11 resolutions including adoption of standalone and consolidated financial statements for F…
• 🟡 Board Meeting2026-09-05Anlon Healthcare held its 13th AGM on September 5, 2025, where shareholders approved audited standalone and consolidated financial statements for FY20…
• Announcement2026-08-13Anlon Healthcare Limited corrected its earlier regulatory filing regarding the acquisition percentages in Apiqo Organics Private Limited and Bizotic L…

🧠 Analyst's Read

Anlon Healthcare is executing a clear transformation strategy centered on scale, vertical integration, and market expansion through acquisitions. While financials show strong top-line growth and improving profitability trends, near-term dilution, margin volatility, and integration risks remain. The company’s success hinges on timely execution of CAPEX and acquisitions, along with sustained price realization. Investors should monitor integration progress, margin recovery, and institutional interest as key catalysts.

Based on filing content and financial data. Not a recommendation.